Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol-Myers

Johnson & Johnson

Merck

Pfizer

Drug stocks have been out of favor due to regulatory concerns. Nevertheless, several top-tier stock experts and contributors to MoneyShow.com see select opportunities for long-term value investors to consider buying large cap pharmaceutical names.

Out-of-Favor Drugs Stocks May be the Right Medicine For Your Portfolio

Allergan

On Wednesday, AbbVie Inc. (NYSE:ABBV), the manufacturer of rheumatoid arthritis treatment Humira, informed the market through PR Newswire that it will issue a corporate loan worth $30 billion in 10 different tranches of senior unsecured notes.

AbbVie Takes on Debt to Buy Allergan

On Wednesday, AbbVie Inc. (NYSE:ABBV), the manufacturer of RA treatment Humira, has informed the market through PR Newswire that it will issue a corporate loan worth $30 billion in 10 different tranches of senior unsecured notes.

AbbVie Inc Takes on Debt to Buy Allergan

This major drug manufacturer pays the highest dividend yield among major drug manufacturers. What is causing this, and is it a viable income play?

Why Does AbbVie Pay a Much Higher Dividend Than Its Peers?

Biogen

Innoviva

Mylan

Novartis

Regeneron Pharmaceuticals

Theravance Biopharma

With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.

7 Biotech Stocks to Buy With Plenty of Power in the Pipeline        

Axalta Coating Systems

Associated Capital Group

Advanced Disposal Services

HeartBeam

Cars.com

Globus Medical

IntriCon

CFA, Chairman andCEO of GAMCO Investors, Inc., Mario Gabelli (Trades, Portfolio), bought shares of the following stocks in both the second and third quarters.

Mario Gabelli Continues to Buy AbbVie, Axalta

Veeva Systems

These three companies have a lot going right for them.

3 Top Healthcare Stocks to Buy Right Now.

AbbVie (ABBV) submits a regulatory application with the FDA seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan.

AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL

Add one more year to AbbVie's impressive streak of dividend hikes.

This Terrific High-Yield Dividend Stock Just Got Even Better

Aurora Cannabis

Cronos Group

CannTrust Holdings

GW Pharmaceuticals

Innovative Industrial Properties

Although recreational weed captures headlines, the real money is on broadly accepted medicinal marijuana stocks.

10 Medical Marijuana Stocks to Cure Your Portfolio

Brinker International

Group 1 Automotive

Hewlett Packard

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

5 High-Flying Stocks Near 52-Week High That Can Scale Higher.

The big pharma company delivered a surprisingly solid performance in the third quarter.

3 Most Important Takeaways From AbbVie's Q3 Results

AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q3 2019 Results - Earnings Call Transcript

Alibaba

Chevron

Funko

Pinterest

United States Steel

Alibaba, Pinterest, AbbVie, Chevron, U.S. Steel and Funko were our top stock trades to watch after a strong day Friday.

6 Top Stock Trades for Monday: BABA, PINS, CVX, ABBV, X & FNKO

AbbVie (ABBV) earnings for the biopharmaceutical company's third quarter of 2019 have ABBV stock up Friday on an EPS and revenue beat.
The post AbbVie Earnings: 5 Things for ABBV Stock Investors to Note appeared first on InvestorPlace.

AbbVie Earnings: 5 Things for ABBV Stock Investors to Note

AbbVie (ABBV) beats on both earnings and revenues in the third quarter. The company ups the lower end of its 2019 guidance for adjusted earnings per share.

AbbVie (ABBV) Beats on Q3 Earnings & Sales, Tweaks EPS View

AbbVie Inc  on Friday forecast 2019 revenue above Wall Street estimates and expressed confidence in future sales of blockbuster wrinkle treatment Botox, which it will acquire with its $63 billion purchase of Allergan Plc.

AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales

AbbVie Inc  said on Friday it was in talks with several parties interested in buying the two assets it intends to divest for the completion of its $63 billion deal to buy drugmaker Allergan Plc.

AbbVie says multiple parties vying for assets related to Allergan deal approval

AbbVie (NYSE: ABBV) reported third-quarter earnings of $2.33 per share on Friday, which beat the analyst consensus estimate of $2.30 by 1.3%.

AbbVie Reports Q3 Earnings Beat

AbbVie earnings and sales slightly topped third-quarter views, while the drug giant also hiked its dividend by 10%. AbbVie stock was little changed.

AbbVie Earnings Top Views, Dividend Hiked

AbbVie Inc  posted quarterly sales above estimates on Friday and raised the lower end of its 2019 profit forecast, helped by strong demand for cancer medicine Imbruvica and a lower-than-expected drop in bestseller Humira's revenue.

AbbVie lifts 2019 profit forecast as Humira helps beat revenue estimates

AbbVie Inc. ABBV, -0.14% reported Friday a third-quarter adjusted profit and revenue that rose above expectations, helped by strength in its immunology and oncology business segments, and raised its earnings outlook.

AbbVie beats earnings expectations and raises outlook, boosts dividend by 10%

CVS Health

Block

The bulls have the advantage on Wall Street, so there are breakout stocks to buy into 2020. CVS, ABBV and SQ are three with bullish charts.

3 Breakout Stocks to Buy for the Rest of 2019

AbbVie (ABBV) is set to report its third quarter results before the opening bell on Friday, November 1.

AbbVie (ABBV) Set to Report Q3 Results: Can Things Turnaround?

Amazon

Costco

CareTrust REIT

Duke Energy

Exxon Mobil

With economic and geopolitical events not providing clearly bullish signals, these buy-and-hold stocks present an ideal opportunity.

News for AbbVie Stock (ABBV)